References
- Coulie PG, Van den Eynde BJ, van der Bruggen P, Boon T. Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy. Nat Rev Cancer 2014; 14:135-46. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24457417; PMID:24457417
- Kubuschok B, Neumann F, Breit R, Sester M, Schormann C, Wagner C, Sester U, Hartmann F, Wagner M, Remberger K et al. Naturally occurring T-cell response against mutated p21 ras oncoprotein in pancreatic cancer. Clin Cancer Res 2006; 12:1365-72. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16489095; PMID:16489095
- Kessler JH, Bres-Vloemans SA, van Veelen PA, de Ru A, Huijbers IJG, Camps M, Mulder A, Offringa R, Drijfhout JW, Leeksma OC et al. BCR-ABL fusion regions as a source of multiple leukemia-specific CD8+ T-cell epitopes. Leukemia 2006; 20:1738-50. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16932347; PMID:16932347
- Pinilla-Ibarz J, Cathcart K, Korontsvit T, Soignet S, Bocchia M, Caggiano J, Lai L, Jimenez J, Kolitz J, Scheinberg DA. Vaccination of patients with chronic myelogenous leukemia with bcr-abl oncogene breakpoint fusion peptides generates specific immune responses. Blood 2000; 95:1781-7. Available from: http://www.ncbi.nlm.nih.gov/pubmed/10688838; PMID:10688838
- Asai H, Fujiwara H, An J, Ochi T, Miyazaki Y, Nagai K, Okamoto S, Mineno J, Kuzushima K, Shiku H et al. Co-introduced functional CCR2 potentiates in vivo anti-lung cancer functionality mediated by T cells double gene-modified to express WT1-specific T-cell receptor. PLoS One 2013; 8:e56820. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3575507&tool=pmcentrez&rendertype=abstract; PMID:23441216; http://dx.doi.org/10.1371/journal.pone.0056820
- Imai N, Ikeda H, Shiku H. [Targeting cancer antigen (MAGE-A4, NY-ESO-1) for immunotherapy]. Nihon Rinsho 2012; 70:2125-9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23259384; PMID:23259384
- Pinilla-Ibarz J, May RJ, Korontsvit T, Gomez M, Kappel B, Zakhaleva V, Zhang RH, Scheinberg DA. Improved human T-cell responses against synthetic HLA-0201 analog peptides derived from the WT1 oncoprotein. Leukemia 2006; 20:2025-33. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16990779; PMID:16990779
- May RJ, Dao T, Pinilla-Ibarz J, Korontsvit T, Zakhaleva V, Zhang RH, Maslak P, Scheinberg DA. Peptide epitopes from the Wilms' tumor 1 oncoprotein stimulate CD4+ and CD8+ T cells that recognize and kill human malignant mesothelioma tumor cells. Clin Cancer Res 2007; 13:4547-55. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17671141; PMID:17671141
- Dermime S, Armstrong A, Hawkins RE, Stern PL. Cancer vaccines and immunotherapy. Br Med Bull 2002; 62:149-62. Available from: http://www.ncbi.nlm.nih.gov/pubmed/12176857; PMID:12176857
- Castelli C, Storkus WJ, Maeurer MJ, Martin DM, Huang EC, Pramanik BN, Nagabhushan TL, Parmiani G, Lotze MT. Mass spectrometric identification of a naturally processed melanoma peptide recognized by CD8+ cytotoxic T lymphocytes. J Exp Med 1995; 181:363-8. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2191826&tool=pmcentrez&rendertype=abstract; PMID:7807017
- Zhang G, Wang L, Cui H, Wang X, Zhang G, Ma J, Han H, He W, Wang W, Zhao Y et al. Anti-melanoma activity of T cells redirected with a TCR-like chimeric antigen receptor. Sci Rep 2014; 4:3571. Available from: http://www.nature.com/srep/2014/140106/srep03571/full/srep03571.html; PMID:24389689
- Klechevsky E, Gallegos M, Denkberg G, Palucka K, Banchereau J, Cohen C, Reiter Y. Antitumor activity of immunotoxins with T-cell receptor-like specificity against human melanoma xenografts. Cancer Res 2008; 68:6360-7. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2728007&tool=pmcentrez&rendertype=abstract; PMID:18676861
- Disis ML, Cheever MA. HER-2/neu protein: a target for antigen-specific immunotherapy of human cancer. Adv Cancer Res 1997; 71:343-71. Available from: http://www.ncbi.nlm.nih.gov/pubmed/9111870; PMID:9111870
- Hörig H, Lee CSD, Kaufman HL. Prostate-specific antigen vaccines for prostate cancer. Expert Opin Biol Ther 2002; 2:395-408. Available from: http://www.ncbi.nlm.nih.gov/pubmed/11955277; PMID:11955277
- LeMaistre CF, Meneghetti C, Howes L, Osborne CK. Targeting the EGF receptor in breast cancer treatment. Breast Cancer Res Treat 1994; 32:97-103. Available from: http://www.ncbi.nlm.nih.gov/pubmed/7819590; PMID:7819590
- Alatrash G, Mittendorf EA, Sergeeva A, Sukhumalchandra P, Qiao N, Zhang M, St John LS, Ruisaard K, Haugen CE, Al-Atrache Z et al. Broad cross-presentation of the hematopoietically derived PR1 antigen on solid tumors leads to susceptibility to PR1-targeted immunotherapy. J Immunol 2012; 189:5476-84. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3504175&tool=pmcentrez&rendertype=abstract; PMID:23105141
- Sergeeva A, Alatrash G, He H, Ruisaard K, Lu S, Wygant J, McIntyre BW, Ma Q, Li D, St John L et al. An anti-PR1/HLA-A2 T-cell receptor-like antibody mediates complement-dependent cytotoxicity against acute myeloid leukemia progenitor cells. Blood 2011; 117:4262-72. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3087478&tool=pmcentrez&rendertype=abstract; PMID:21296998; http://dx.doi.org/10.1182/blood-2010-07-299248
- Disis ML. Mechanism of action of immunotherapy. Semin Oncol 2014; 41(Suppl 5):S3-13. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25438997; PMID:25438997
- Baxevanis CN, Papamichail M, Perez SA. Therapeutic cancer vaccines: a long and winding road to success. Expert Rev Vaccines 2014; 13:131-44. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24224539; PMID:24224539
- Schmitt TM, Aggen DH, Stromnes IM, Dossett ML, Richman SA, Kranz DM, Greenberg PD. Enhanced-affinity murine T-cell receptors for tumor/self-antigens can be safe in gene therapy despite surpassing the threshold for thymic selection. Blood 2013; 122:348-56. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3716200&tool=pmcentrez&rendertype=abstract; PMID:23673862; http://dx.doi.org/10.1182/blood-2013-01-478164
- Gill S, June CH. Going viral: chimeric antigen receptor T-cell therapy for hematological malignancies. Immunol Rev 2015; 263:68-89. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25510272; PMID:25510272
- Scott AM, Wolchok JD, Old LJ. Antibody therapy of cancer. Nat Rev Cancer 2012; 12:278-87. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22437872; PMID:22437872
- Dahan R, Reiter Y. T-cell-receptor-like antibodies - generation, function and applications. Expert Rev Mol Med 2012; 14:e6. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22361332; PMID:22361332
- Dao T, Yan S, Veomett N, Pankov D, Zhou L, Korontsvit T, Scott A, Whitten J, Maslak P, Casey E et al. Targeting the intracellular WT1 oncogene product with a therapeutic human antibody. Sci Transl Med 2013; 5:176ra33. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3963696&tool=pmcentrez&rendertype=abstract; PMID:23486779
- Veomett N, Dao T, Liu H, Xiang J, Pankov D, Dubrovsky L, Whitten JA, Park S-M, Korontsvit T, Zakhaleva V et al. Therapeutic efficacy of an Fc-enhanced TCR-like antibody to the intracellular WT1 oncoprotein. Clin Cancer Res 2014; 20:4036-46. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24850840; PMID:24850840
- Dubrovsky L, Pankov D, Brea EJ, Dao T, Scott A, Yan S, O'Reilly RJ, Liu C, Scheinberg DA. A TCR-mimic antibody to WT1 bypasses tyrosine kinase inhibitor resistance in human BCR-ABL+ leukemias. Blood 2014; 123:3296-304. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24723681; PMID:24723681; http://dx.doi.org/10.1182/blood-2014-01-549022
- Sastry KSR, Too CT, Kaur K, Gehring AJ, Low L, Javiad A, Pollicino T, Li L, Kennedy PTF, Lopatin U et al. Targeting hepatitis B virus-infected cells with a T-cell receptor-like antibody. J Virol 2011; 85:1935-42. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3067764&tool=pmcentrez&rendertype=abstract; PMID:21159876
- Polakova K, Plaksin D, Chung DH, Belyakov IM, Berzofsky JA, Margulies DH. Antibodies Directed Against the MHC-I Molecule H-2Dd Complexed with an Antigenic Peptide: Similarities to a T Cell Receptor with the Same Specificity. J Immunol 2000; 165:5703-12. Available from: http://www.jimmunol.org/content/165/10/5703.full; PMID:11067928
- Kim S, Pinto AK, Myers NB, Hawkins O, Doll K, Kaabinejadian S, Netland J, Bevan MJ, Weidanz JA, Hildebrand WH et al. A novel T-cell receptor mimic defines dendritic cells that present an immunodominant West Nile virus epitope in mice. Eur J Immunol 2014; 44:1936-46. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24723377; PMID:24723377
- Willemsen RA, Ronteltap C, Chames P, Debets R, Bolhuis RLH. T cell retargeting with MHC class I-restricted antibodies: the CD28 costimulatory domain enhances antigen-specific cytotoxicity and cytokine production. J Immunol 2005; 174:7853-8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15944290; PMID:15944290
- Epel M, Carmi I, Soueid-Baumgarten S, Oh SK, Bera T, Pastan I, Berzofsky J, Reiter Y. Targeting TARP, a novel breast and prostate tumor-associated antigen, with T cell receptor-like human recombinant antibodies. Eur J Immunol 2008; 38:1706-20. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2682370&tool=pmcentrez&rendertype=abstract; PMID:18446790
- Verma B, Hawkins OE, Neethling FA, Caseltine SL, Largo SR, Hildebrand WH, Weidanz JA. Direct discovery and validation of a peptide/MHC epitope expressed in primary human breast cancer cells using a TCRm monoclonal antibody with profound antitumor properties. Cancer Immunol Immunother 2010; 59:563-73. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19779714; PMID:19779714; http://dx.doi.org/10.1007/s00262-009-0774-8
- Verma B, Jain R, Caseltine S, Rennels A, Bhattacharya R, Markiewski MM, Rawat A, Neethling F, Bickel U, Weidanz JA. TCR mimic monoclonal antibodies induce apoptosis of tumor cells via immune effector-independent mechanisms. J Immunol 2011; 186:3265-76. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21282517; PMID:21282517; http://dx.doi.org/10.4049/jimmunol.1002376
- Verma B, Neethling FA, Caseltine S, Fabrizio G, Largo S, Duty JA, Tabaczewski P, Weidanz JA. TCR mimic monoclonal antibody targets a specific peptide/HLA class I complex and significantly impedes tumor growth in vivo using breast cancer models. J Immunol 2010; 184:2156-65. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20065111; PMID:20065111; http://dx.doi.org/10.4049/jimmunol.0902414
- Jain R, Rawat A, Verma B, Markiewski MM, Weidanz JA. Antitumor activity of a monoclonal antibody targeting major histocompatibility complex class I-Her2 peptide complexes. J Natl Cancer Inst 2013; 105:202-18. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3611852&tool=pmcentrez&rendertype=abstract; PMID:23300219; http://dx.doi.org/10.1093/jnci/djs521
- Yewdell JW, Reits E, Neefjes J. Making sense of mass destruction: quantitating MHC class I antigen presentation. Nat Rev Immunol 2003; 3:952-61. Available from: http://www.ncbi.nlm.nih.gov/pubmed/14647477; PMID:14647477; http://dx.doi.org/10.1038/nri1250
- Bourdetsky D, Schmelzer CEH, Admon A. The nature and extent of contributions by defective ribosome products to the HLA peptidome. Proc Natl Acad Sci U S A 2014; 111:E1591-9. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4000780&tool=pmcentrez&rendertype=abstract; PMID:24715725; http://dx.doi.org/10.1073/pnas.1321902111
- Bassani-Sternberg M, Pletscher-Frankild S, Jensen LJ, Mann M. Mass spectrometry of HLA-I peptidomes reveals strong effects of protein abundance and turnover on antigen presentation. Mol Cell Proteomics 2015; Available from: http://www.ncbi.nlm.nih.gov/pubmed/25576301; PMID:25576301
- Praveen PVK, Yaneva R, Kalbacher H, Springer S. Tapasin edits peptides on MHC class I molecules by accelerating peptide exchange. Eur J Immunol 2010; 40:214-24. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20017190; PMID:20017190; http://dx.doi.org/10.1002/eji.200939342
- Neefjes J, Jongsma MLM, Paul P, Bakke O. Towards a systems understanding of MHC class I and MHC class II antigen presentation. Nat Rev Immunol 2011; 11:823-36. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22076556; PMID:22076556
- Lu X, Gibbs JS, Hickman HD, David A, Dolan BP, Jin Y, Kranz DM, Bennink JR, Yewdell JW, Varma R. Endogenous viral antigen processing generates peptide-specific MHC class I cell-surface clusters. Proc Natl Acad Sci U S A 2012; 109:15407-12. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3458372&tool=pmcentrez&rendertype=abstract; PMID:22949678; http://dx.doi.org/10.1073/pnas.1208696109
- Khanna R. Tumour surveillance: missing peptides and MHC molecules. Immunol Cell Biol 1998; 76:20-6. Available from: http://www.ncbi.nlm.nih.gov/pubmed/9553772; PMID:9553772; http://dx.doi.org/10.1046/j.1440-1711.1998.00717.x
- Angell TE, Lechner MG, Jang JK, LoPresti JS, Epstein AL. MHC class I loss is a frequent mechanism of immune escape in papillary thyroid cancer that is reversed by interferon and selumetinib treatment in vitro. Clin Cancer Res 2014; 20:6034-44. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25294906; PMID:25294906; http://dx.doi.org/10.1158/1078-0432.CCR-14-0879
- Hallermalm K, Seki K, Wei C, Castelli C, Rivoltini L, Kiessling R, Levitskaya J. Tumor necrosis factor-α induces coordinated changes in major histocompatibility class I presentation pathway, resulting in increased stability of class I complexes at the cell surface. Blood 2001; 98:1108-15; PMID:11493458; http://dx.doi.org/10.1182/blood.V98.4.1108
- Wan S, Pestka S, Jubin RG, Lyu YL, Tsai YC, Liu LF. Chemotherapeutics and radiation stimulate MHC class i expression through elevated interferon-beta signaling in breast cancer cells. PLoS One 2012; 7:e32542; PMID:22396773; http://dx.doi.org/10.1371/annotation/3155a3e9-5fbe-435c-a07a-e9a4846ec0b6
- Fortier M-H, Caron E, Hardy M-P, Voisin G, Lemieux S, Perreault C, Thibault P. The MHC class I peptide repertoire is molded by the transcriptome. J Exp Med 2008; 205:595-610. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2275383&tool=pmcentrez&rendertype=abstract; PMID:18299400; http://dx.doi.org/10.1084/jem.20071985
- Warren RL, Holt RA. A census of predicted mutational epitopes suitable for immunologic cancer control. Hum Immunol 2010; 71:245-54. Available from: http://www.sciencedirect.com/science/article/pii/S0198885909006612; PMID:20035814; http://dx.doi.org/10.1016/j.humimm.2009.12.007
- Worley BS, van den Broeke LT, Goletz TJ, Pendleton CD, Daschbach EM, Thomas EK, Marincola FM, Helman LJ, Berzofsky JA. Antigenicity of fusion proteins from sarcoma-associated chromosomal translocations. Cancer Res 2001; 61:6868-75. Available from: http://cancerres.aacrjournals.org/content/61/18/6868.full; PMID:11559563
- Tsang KY, Zaremba S, Nieroda CA, Zhu MZ, Hamilton JM, Schlom J. Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine. J Natl Cancer Inst 1995; 87:982-90. Available from: http://www.ncbi.nlm.nih.gov/pubmed/7629885; PMID:7629885; http://dx.doi.org/10.1093/jnci/87.13.982
- Van der Bruggen P, Traversari C, Chomez P, Lurquin C, De Plaen E, Van den Eynde B, Knuth A, Boon T. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991; 254:1643-7. Available from: http://www.ncbi.nlm.nih.gov/pubmed/1840703; PMID:1840703; http://dx.doi.org/10.1126/science.1840703
- Correale P, Walmsley K, Nieroda C, Zaremba S, Zhu M, Schlom J, Tsang KY. In vitro generation of human cytotoxic T lymphocytes specific for peptides derived from prostate-specific antigen. J Natl Cancer Inst 1997; 89:293-300. Available from: http://www.ncbi.nlm.nih.gov/pubmed/9048833; PMID:9048833; http://dx.doi.org/10.1093/jnci/89.4.293
- Morgan RA, Chinnasamy N, Abate-Daga D, Gros A, Robbins PF, Zheng Z, Dudley ME, Feldman SA, Yang JC, Sherry RM et al. Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy. J Immunother 2013; 36:133-51. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3581823&tool=pmcentrez&rendertype=abstract; PMID:23377668; http://dx.doi.org/10.1097/CJI.0b013e3182829903
- Oleinika K, Nibbs RJ, Graham GJ, Fraser A. R. Suppression, subversion and escape: The role of regulatory T cells in cancer progression. Clin Exp Immunol 2013; 171:36-5; PMID:23199321; http://dx.doi.org/10.1111/j.1365-2249.2012.04657.x
- Noy R, Pollard JW. Tumor-associated macrophages: from mechanisms to therapy. Immunity [Internet] 2014; 41:49-61; PMID:25035953; http://dx.doi.org/10.1016/j.immuni.2014.06.010
- Ries CH, Cannarile MA, Hoves S, Benz J, Wartha K, Runza V, Rey-Giraud F, Pradel LP, Feuerhake F, Klaman I et al. Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy. Cancer Cell 2014; 25:846-59; PMID:24898549; http://dx.doi.org/10.1016/j.ccr.2014.05.016
- Matsui K, Boniface J, Reay P, Schild H, Fazekas de St Groth B, Davis M. Low affinity interaction of peptide-MHC complexes with T cell receptors. Science 1991; 254:1788-91. Available from: http://www.sciencemag.org/content/254/5039/1788.short; PMID:1763329; http://dx.doi.org/10.1126/science.1763329
- Mareeva T, Martinez-Hackert E, Sykulev Y. How a T cell receptor-like antibody recognizes major histocompatibility complex-bound peptide. J Biol Chem 2008; 283:29053-9. Available from: http://www.jbc.org/content/283/43/29053.long; PMID:18703505; http://dx.doi.org/10.1074/jbc.M804996200
- Alam SM, Travers PJ, Wung JL, Nasholds W, Redpath S, Jameson SC, Gascoigne NR. T-cell-receptor affinity and thymocyte positive selection. Nature 1996; 381:616-20; PMID:8637599; http://dx.doi.org/10.1038/381616a0
- Devine L, Sun J, Barr MR, Kavathas PB. Orientation of the Ig domains of CD8 alpha beta relative to MHC class I. J Immunol 1999; 162:846-51. Available from: http://www.jimmunol.org/content/162/2/846.full; PMID:9916707
- Lenschow DJ, Walunas TL, Bluestone JA. CD28/B7 system of T cell costimulation. Annu Rev Immunol 1996; 14:233-58; PMID:8717514; http://dx.doi.org/10.1146/annurev.immunol.14.1.233
- Ding Y-H, Smith KJ, Garboczi DN, Utz U, Biddison WE, Wiley DC. Two human T cell receptors bind in a similar diagonal mode to the HLA-A2/Tax peptide complex using different TCR amino acids. Immunity 1998; 8:403-11. Available from: http://www.sciencedirect.com/science/article/pii/S1074761300805464; PMID:9586631; http://dx.doi.org/10.1016/S1074-7613(00)80546-4
- Garcia KC. Structural basis of plasticity in T cell receptor recognition of a self peptide-MHC antigen. Science 1998; 279:1166-72. Available from: http://www.sciencemag.org/content/279/5354/1166.long; PMID:9469799
- Garboczi DN, Ghosh P, Utz U, Fan QR, Biddison WE, Wiley DC. Structure of the complex between human T-cell receptor, viral peptide and HLA-A2. Nature 1996; 384:134-41; PMID:8906788; http://dx.doi.org/10.1038/384134a0
- Stewart-jones G, Hombach A, Shenderov E, Held G, Fischer E, Kleber S, Stenner-liewen F, Mcmichael A, Knuth A, Abken H et al. Rational development of high-affinity T-cell receptor-like antibodies. Proc Natl Acad Sci 2009; 106:10872-2; PMID:19307587; http://dx.doi.org/10.1073/pnas.0905399106
- Chapuis AG, Ragnarsson GB, Nguyen HN, Chaney CN, Pufnock JS, Schmitt TM, Duerkopp N, Roberts IM, Pogosov GL, Ho WY et al. Transferred WT1-reactive CD8+ T cells can mediate antileukemic activity and persist in post-transplant patients. Sci Transl Med 2013; 5:174ra27. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3678970&tool=pmcentrez&rendertype=abstract; PMID:23447018
- Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med 2004; 10:909-15; PMID:15340416; http://dx.doi.org/10.1038/nm1100
- June CH. Principles of adoptive T cell cancer therapy. J Clin Invest 2007; 17:1204-12. Available from: http://www.jci.org/articles/view/31446#SEC6; PMID:17476350
- Lindau D, Gielen P, Kroesen M, Wesseling P, Adema GJ. The immunosuppressive tumour network: myeloid-derived suppressor cells, regulatory T cells and natural killer T cells. Immunology 2013; 138:105-15. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3575763&tool=pmcentrez&rendertype=abstract; PMID:23216602; http://dx.doi.org/10.1111/imm.12036
- Wittman VP, Woodburn D, Nguyen T, Neethling FA, Wright S, Weidanz JA. Antibody targeting to a class I MHC-Peptide epitope promotes tumor cell death. J Immunol 2006; 177:4187-95. Available from: http://www.jimmunol.org/content/177/6/4187.full; PMID:16951384
- Kerndrup G, Meyer K, Ellegaard J, Hokland P. Natural killer (NK)-cell activity and antibody-dependent cellular cytotoxicity (ADCC) in primary preleukemic syndrome. Leuk Res 1984; 8:239-47. Available from: http://www.ncbi.nlm.nih.gov/pubmed/6717064; PMID:6717064
- Munn DH, Cheung NK. Phagocytosis of tumor cells by human monocytes cultured in recombinant macrophage colony-stimulating factor. J Exp Med 1990; 172:231-7. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2188164&tool=pmcentrez&rendertype=abstract; PMID:2193096
- Van der Bij GJ, Bögels M, Otten MA, Oosterling SJ, Kuppen PJ, Meijer S, Beelen RHJ, van Egmond M. Experimentally induced liver metastases from colorectal cancer can be prevented by mononuclear phagocyte-mediated monoclonal antibody therapy. J Hepatol 2010; 53:677-85. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20619916; PMID:20619916
- Dallegri F, Patrone F, Holm G, Gahrton G, Sacchetti C. Neutrophil-mediated antibody-dependent cellular cytotoxicity against erythrocytes. Mechanisms of target cell destruction. Clin Exp Immunol 1983; 52:613-9. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1536050&tool=pmcentrez&rendertype=abstract; PMID:6307559
- Jefferis R. Glycosylation of recombinant antibody therapeutics. Biotechnol Prog 2005; 21:11-6. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15903235; PMID:15903235
- Smith P, DiLillo DJ, Bournazos S, Li F, Ravetch JV. Mouse model recapitulating human Fcγ receptor structural and functional diversity. Proc Natl Acad Sci U S A 2012; 109:6181-6. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3341029&tool=pmcentrez&rendertype=abstract; PMID:22474370
- McDevitt MR, Ma D, Lai LT, Simon J, Borchardt P, Frank RK, Wu K, Pellegrini V, Curcio MJ, Miederer M et al. Tumor therapy with targeted atomic nanogenerators. Science 2001; 294:1537-40. Available from: http://www.sciencemag.org/content/294/5546/1537.long; PMID:11711678; http://dx.doi.org/10.1126/science.1064126
- Maguire WF, McDevitt MR, Smith-Jones PM, Scheinberg DA. Efficient 1-step radiolabeling of monoclonal antibodies to high specific activity with 225Ac for α-particle radioimmunotherapy of cancer. J Nucl Med 2014; 55:1492-8. Available from: http://jnm.snmjournals.org/content/55/9/1492.long; PMID:24982438; http://dx.doi.org/10.2967/jnumed.114.138347
- Chames P, Baty D. Bispecific antibodies for cancer therapy: the light at the end of the tunnel? MAbs 2009; 1:539-47. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2791310&tool=pmcentrez&rendertype=abstract; PMID:20073127; http://dx.doi.org/10.4161/mabs.1.6.10015
- Huehls AM, Coupet TA, Sentman CL. Bispecific T-cell engagers for cancer immunotherapy. Immunol Cell Biol 2014; PMID:25367186; http://dx.doi.org/10.1038/icb.2014.93
- Curran KJ, Pegram HJ, Brentjens RJ. Chimeric antigen receptors for T cell immunotherapy: current understanding and future directions. J Gene Med 2012; 14:405-15. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22262649; PMID:22262649; http://dx.doi.org/10.1002/jgm.2604